QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs

QDX, a computational drug discovery company, today announced a collaboration with Prelude Therapeutics, a clinical-stage precision oncology company, targeting undisclosed, previously undrugged oncology targets.

QDX integrates its world-leading quantum mechanical simulation technology, supercomputing, artificial intelligence, and deep drug discovery expertise to advance computational chemistry and drug discovery.

Words from CSO: Prelude

Peggy Scherle, PhD, CSO of Prelude, commented: ""Computational approaches to drug discovery are showing increasing promise. We are pleased to work with the talented team at QDX to leverage their blend of high-performance computing, quantum simulations, and AI on these historically challenging targets.

Words from the CEO: QDX

Loong Wang, Co-Founder and CEO of QDX, stated: ""We are thrilled to be working with the team at Prelude to help break new ground on these programs. This collaboration with Prelude exemplifies the kind of bespoke partnerships that QDX engages in across academia and industry, deploying our best-in-class quantum technology, our massively parallel supercomputing, and AI systems.""

Words from MD: QDX

Kelvin Neu, MD, Co-Founder and Chair of QDX, added: ""The accomplished biology and chemistry teams at Prelude have been very productive, generating a pipeline of small molecules against important and often challenging oncology targets. QDX has built a powerful platform by thoughtfully integrating complementary disciplines, guided by the practical needs and challenges of novel drug discovery, with a particular focus on select traditionally difficult-to-crack areas. We are honored that Prelude has chosen QDX to support them on these challenging targets and look forward to a productive collaboration.""

About QDX

• QDX is a computational drug discovery company integrating quantum mechanical simulations, supercomputing, and artificial intelligence. 
• By developing new systems and algorithms from ground up and optimizing existing software for modern hardware, QDX achieves large-scale molecular dynamics and quantum simulations with unmatched speed and scale. 
• From small molecules to entire protein complexes, QDX makes quantum simulations pragmatic and relevant in applications such as drug discovery and materials science.

QDX's aim

• QDX's cross-disciplinary team focuses on industrializing, specializing, and delivering on the promise of classical and quantum computational chemistry for a range of applications and industries. 
• Initially focusing on drug discovery, QDX collaborates with researchers and companies on complex projects, providing unique insights and capabilities through large-scale computations, quantum simulations, proprietary high-quality quantum training data, AI, and custom software. QDX is a globally-minded company based in Singapore and Australia.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!